Zachary Sorrentino, MD, PhD
Physician–Scientist | Neurosurgery Resident | Leadership Grant Recipient (2020) | KTCT Research Grant Recipient (2025), University of Florida
Biography
Zachary Sorrentino’s path into neuroscience was shaped as much by lived experience as by academic ambition. Raised in South Florida by two emergency room physicians, he grew up with a front-row view of medicine’s capacity to save lives-and its limits. Dinner-table conversations often centered on patients, ethical decisions, and the quiet toll of neurological injury. Long before he could name specific diseases, Sorrentino understood that damage to the brain could alter not only physical ability, but memory, personality, and identity.
He entered the University of Florida, drawn to both physics and biochemistry, unsure whether he would ultimately pursue medicine or science. Rather than choosing between them, he committed to both, enrolling in an MD-PhD program that integrated clinical training with mechanistic research. During his doctoral work, he studied molecular pathways involved in Parkinson’s disease progression, focusing on how misfolded proteins propagate through neural circuits.
Medical school reinforced that choice. As he rotated through organ systems, Sorrentino noticed a striking pattern. While many fields offered increasingly effective interventions, neurology often ended with uncertainty. Treatments managed symptoms but rarely altered disease trajectories.
“That absence of answers stuck with me,” he recalls. “It made the brain feel like the last true frontier in medicine.”
That realization became deeply personal midway through his training, when his father suffered a devastating ischemic stroke. Although he survived, the event permanently altered his cognition and personality. Witnessing this loss firsthand strengthened his resolve to develop interventions that can prevent or mitigate such outcomes, aligning his personal experience with his commitment to translational neuroscience and neurosurgery.
“It was one thing to study neurological disease,” Sorrentino says. “It was another to watch it erase someone you love.”
The experience solidified his commitment to neurosurgery and translational neuroscience-fields in which direct access to the brain enables intervention rather than observation alone.
Biography
Zachary Sorrentino’s path into neuroscience was shaped as much by lived experience as by academic ambition. Raised in South Florida by two emergency room physicians, he grew up with a front-row view of medicine’s capacity to save lives-and its limits. Dinner-table conversations often centered on patients, ethical decisions, and the quiet toll of neurological injury. Long before he could name specific diseases, Sorrentino understood that damage to the brain could alter not only physical ability, but memory, personality, and identity.
He entered the University of Florida, drawn to both physics and biochemistry, unsure whether he would ultimately pursue medicine or science. Rather than choosing between them, he committed to both, enrolling in an MD-PhD program that integrated clinical training with mechanistic research. During his doctoral work, he studied molecular pathways involved in Parkinson’s disease progression, focusing on how misfolded proteins propagate through neural circuits.
Medical school reinforced that choice. As he rotated through organ systems, Sorrentino noticed a striking pattern. While many fields offered increasingly effective interventions, neurology often ended with uncertainty. Treatments managed symptoms but rarely altered disease trajectories.
“That absence of answers stuck with me,” he recalls. “It made the brain feel like the last true frontier in medicine.”
That realization became deeply personal midway through his training, when his father suffered a devastating ischemic stroke. Although he survived, the event permanently altered his cognition and personality. Witnessing this loss firsthand strengthened his resolve to develop interventions that can prevent or mitigate such outcomes, aligning his personal experience with his commitment to translational neuroscience and neurosurgery.
“It was one thing to study neurological disease,” Sorrentino says. “It was another to watch it erase someone you love.”
The experience solidified his commitment to neurosurgery and translational neuroscience-fields in which direct access to the brain enables intervention rather than observation alone.
Research Focus
During neurosurgical residency, Sorrentino gravitated toward disorders that sit at the intersection of structure, circuitry, and degeneration. He trained extensively in deep brain stimulation, stroke thrombectomy, and neuroendovascular techniques-procedures that allow clinicians to reach precise brain regions with minimal invasiveness.
While assisting in deep-brain stimulation surgeries for Parkinson’s disease, Sorrentino noticed something others had overlooked. Guide cannulas used during the procedure, typically discarded as surgical waste, contained microscopic traces of brain tissue from regions not yet overtly affected by disease.
“That tissue represents a moment in time we rarely get access to,” he explains. “It’s the brain that’s at risk, but not yet destroyed.”
Recognizing the scientific opportunity, Sorrentino developed protocols to collect and analyze these samples without altering surgical risk or workflow. His early studies identified disease-associated protein signatures, such as pathogenic alpha-synuclein, before clinical symptoms appeared, advancing understanding of neurodegeneration's earliest molecular events and highlighting potential therapeutic targets.
In parallel, Sorrentino began developing a second line of research that reflects his dual identity as surgeon and scientist: neuroendovascular delivery of therapeutics to the brain. While many experimental drugs fail because they cannot cross the blood–brain barrier or cause systemic toxicity, neurosurgeons routinely navigate catheters into cerebral vessels to treat stroke and aneurysms.
“The technology already exists,” he notes. “We just haven’t fully adapted it for neurodegeneration.”
By building a novel mouse model that mimics human neuroendovascular access, Sorrentino demonstrated that large molecules-including antibodies and gene-therapy vectors-can be delivered directly to targeted brain regions while minimizing systemic exposure.
Sorrentino’s trajectory might have stalled at several points without early validation. In 2020, during a financially and professionally precarious period early in residency, he received a Karen Toffler Charitable Trust Leadership Grant. At the time, he was newly married and balancing intense clinical demands with uncertain research prospects.
The Leadership Grant provided breathing room-both literal and psychological-allowing him to remain engaged in research during a demanding clinical phase. It also reinforced his identity as a future clinician-scientist at a time when many trainees feel pressure to narrow their focus.
“That support helped me stay in the game,” Sorrentino reflects. “It told me that leadership in science starts with potential, not position.”
Building on that early momentum, Sorrentino received a Toffler Scholar grant for 2026, marking a significant next phase in his work. Unlike the Leadership Grant, which helped sustain engagement during training, the 2026 award is to accelerate translation.
The funding will support the expansion of his patient-derived brain tissue program, enabling larger-scale molecular profiling of early-stage neurodegeneration using tissue collected during deep brain stimulation procedures. It will also advance his neuroendovascular delivery platform, supporting optimization of targeted catheter-based approaches and preclinical testing of therapeutic candidates that have historically struggled to cross the blood-brain barrier, paving the way for innovative treatments.
“This grant lets me connect ideas that were previously running in parallel,” Sorrentino explains. “It allows us to link what we see in patients, what we measure in tissue, and how we deliver therapy in a way that finally feels integrated.”
The award also provides protected research time during residency, a rare and critical resource. With that support, Sorrentino is deepening collaborations with neuroscientists, engineers, and translational researchers while continuing to refine surgical techniques that enable discovery alongside care.
Looking ahead, Sorrentino envisions neurosurgeons leading early, precise interventions to slow neurodegeneration. This future aims to motivate institutions and students to pursue innovative, impactful research in neurosurgery and neuroscience.
For Sorrentino, the goal is clear.
“Treating disease is important,” he says. “But protecting identity-that’s what matters most.”